---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-24-000836"
form_type: "8-K"
ticker: "INSM"
cik: "0001104506"
company_name: "INSMED Inc"
filed_at: "2024-01-05T23:59:59+00:00"
generated_at: "2026-06-07T02:55:01.648864+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Insmed reports prelim 2023 ARIKAYCE sales of ~$305.2M; guides 2024 to $340-360M

## Summary
- ARIKAYCE 2023 global net sales ~$305.2M, exceeding upper end of guidance, 24% YoY growth.
- 2024 ARIKAYCE revenue guidance $340-360M (midpoint 15% growth).
- Phase 3 ASPEN (brensocatib) topline data expected latter part of Q2 2024; potential U.S. launch mid-2025.
- TPIP Phase 2 PH-ILD study enrollment completed (39 patients); topline data expected Q2 2024.
- Phase 3 ENCORE (ARIKAYCE label expansion) topline readout expected 2025; FDA feedback received on ARISE.

## SEC filing metadata
- accession: 0001140361-24-000836
- form_type: 8-K
- ticker: INSM
- cik: 0001104506
- company_name: INSMED Inc
- filed_at: 2024-01-05T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1104506/000114036124000836/0001140361-24-000836-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1104506/000114036124000836/ef20017898_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-24-000836
- JSON: https://secwatch.observer/filing/0001140361-24-000836.json
- Plain text: https://secwatch.observer/filing/0001140361-24-000836.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.